Leptospiral  ||| S:0 E:12 ||| JJ
uveitis  ||| S:12 E:20 ||| NN
-  ||| S:20 E:22 ||| :
there  ||| S:22 E:28 ||| EX
is  ||| S:28 E:31 ||| VBZ
more  ||| S:31 E:36 ||| JJR
to  ||| S:36 E:39 ||| TO
it  ||| S:39 E:42 ||| PRP
than  ||| S:42 E:47 ||| IN
meets  ||| S:47 E:53 ||| VBG
the  ||| S:53 E:57 ||| DT
eye ||| S:57 E:60 ||| NN
!  ||| S:60 E:62 ||| .
Leptospirosis ||| S:62 E:75 ||| NNP
,  ||| S:75 E:77 ||| ,
caused  ||| S:77 E:84 ||| VBN
by  ||| S:84 E:87 ||| IN
pathogenic  ||| S:87 E:98 ||| JJ
species  ||| S:98 E:106 ||| NNS
of  ||| S:106 E:109 ||| IN
genus  ||| S:109 E:115 ||| JJ
Leptospira ||| S:115 E:125 ||| NNP
,  ||| S:125 E:127 ||| ,
is  ||| S:127 E:130 ||| VBZ
a  ||| S:130 E:132 ||| DT
highly  ||| S:132 E:139 ||| RB
prevalent  ||| S:139 E:149 ||| JJ
zoonotic  ||| S:149 E:158 ||| JJ
disease  ||| S:158 E:166 ||| NN
throughout  ||| S:166 E:177 ||| IN
many  ||| S:177 E:182 ||| JJ
parts  ||| S:182 E:188 ||| NNS
of  ||| S:188 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
world ||| S:195 E:200 ||| NN
,  ||| S:200 E:202 ||| ,
and  ||| S:202 E:206 ||| CC
an  ||| S:206 E:209 ||| DT
important  ||| S:209 E:219 ||| JJ
emerging  ||| S:219 E:228 ||| VBG
disease  ||| S:228 E:236 ||| NN
within  ||| S:236 E:243 ||| IN
the  ||| S:243 E:247 ||| DT
United  ||| S:247 E:254 ||| NNP
States ||| S:254 E:260 ||| NNPS
.  ||| S:260 E:262 ||| .
Uveitis  ||| S:262 E:270 ||| NNP
is  ||| S:270 E:273 ||| VBZ
a  ||| S:273 E:275 ||| DT
common  ||| S:275 E:282 ||| JJ
complication  ||| S:282 E:295 ||| NN
of  ||| S:295 E:298 ||| IN
systemic  ||| S:298 E:307 ||| JJ
infection  ||| S:307 E:317 ||| NN
in  ||| S:317 E:320 ||| IN
humans ||| S:320 E:326 ||| NNS
.  ||| S:326 E:328 ||| .
A  ||| S:328 E:330 ||| DT
similar  ||| S:330 E:338 ||| JJ
condition  ||| S:338 E:348 ||| NN
in  ||| S:348 E:351 ||| IN
horses  ||| S:351 E:358 ||| NNS
is  ||| S:358 E:361 ||| VBZ
characterized  ||| S:361 E:375 ||| VBN
by  ||| S:375 E:378 ||| IN
recurrent  ||| S:378 E:388 ||| JJ
bouts  ||| S:388 E:394 ||| NNS
of  ||| S:394 E:397 ||| IN
inflammation ||| S:397 E:409 ||| NN
.  ||| S:409 E:411 ||| .
In  ||| S:411 E:414 ||| IN
this  ||| S:414 E:419 ||| DT
article ||| S:419 E:426 ||| NN
,  ||| S:426 E:428 ||| ,
we  ||| S:428 E:431 ||| PRP
review  ||| S:431 E:438 ||| VB
advances  ||| S:438 E:447 ||| NNS
in  ||| S:447 E:450 ||| IN
our  ||| S:450 E:454 ||| PRP$
understanding  ||| S:454 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
leptospiral  ||| S:471 E:483 ||| JJ
uveitis  ||| S:483 E:491 ||| NN
and  ||| S:491 E:495 ||| CC
its  ||| S:495 E:499 ||| PRP$
pathogenic  ||| S:499 E:510 ||| JJ
mechanisms ||| S:510 E:520 ||| NNS
.  ||| S:520 E:522 ||| .
